XORTX Therapeutics, Inc. (XRTX)
0.9702
-0.04
(-3.94%)
USD |
NASDAQ |
Oct 20, 16:00
1.05
+0.08
(+8.23%)
After-Hours: 20:00
XORTX Therapeutics Max Drawdown (5Y) : 99.46% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 99.46% |
| August 31, 2026 | 99.46% |
| July 31, 2026 | 99.46% |
| June 30, 2026 | 99.46% |
| May 31, 2026 | 99.46% |
| April 30, 2026 | 99.46% |
| March 31, 2026 | 99.46% |
| February 28, 2026 | 99.39% |
| January 31, 2026 | 99.24% |
| December 31, 2025 | 99.18% |
| November 30, 2025 | 99.18% |
| October 31, 2025 | 99.07% |
| September 30, 2025 | 98.88% |
| August 31, 2025 | 98.88% |
| July 31, 2025 | 98.88% |
| June 30, 2025 | 98.76% |
| May 31, 2025 | 98.73% |
| April 30, 2025 | 98.73% |
| March 31, 2025 | 98.73% |
| February 28, 2025 | 98.73% |
| January 31, 2025 | 98.59% |
| December 31, 2024 | 98.31% |
| November 30, 2024 | 98.22% |
| October 31, 2024 | 98.22% |
| September 30, 2024 | 98.22% |
| Date | Value |
|---|---|
| August 31, 2024 | 98.22% |
| July 31, 2024 | 97.50% |
| June 30, 2024 | 97.05% |
| May 31, 2024 | 96.88% |
| April 30, 2024 | 96.88% |
| March 31, 2024 | 96.88% |
| February 29, 2024 | 96.88% |
| January 31, 2024 | 96.88% |
| December 31, 2023 | 96.88% |
| November 30, 2023 | 96.43% |
| October 31, 2023 | 96.37% |
| September 30, 2023 | 93.72% |
| August 31, 2023 | 93.72% |
| July 31, 2023 | 93.72% |
| June 30, 2023 | 93.72% |
| May 31, 2023 | 93.72% |
| April 30, 2023 | 93.72% |
| March 31, 2023 | 93.71% |
| February 28, 2023 | 92.25% |
| January 31, 2023 | 91.78% |
| December 31, 2022 | 89.81% |
| November 30, 2022 | 89.39% |
| October 31, 2022 | 88.41% |
| September 30, 2022 | 86.94% |
| August 31, 2022 | 83.80% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Lexaria Bioscience Corp. | 99.02% |
| InMed Pharmaceuticals, Inc. | 99.97% |
| Target Group, Inc. (Canada) | 99.99% |
| NervGen Pharma Corp. | 73.37% |
| Milestone Pharmaceuticals, Inc. | 95.25% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -71.71 |
| Beta (5Y) | 0.5846 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 80.25% |
| Historical Sharpe Ratio (5Y) | -0.8207 |
| Historical Sortino (5Y) | -1.593 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 32.40% |